Advanced

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Sahebi, Firoozeh; Iacobelli, Simona; Sbianchi, Giulia; Koster, Linda; Blaise, Didier; Reményi, Péter; Russell, Nigel H.; Ljungman, Per; Kobbe, Guido and Apperley, Jane, et al. (2018) In Biology of Blood and Marrow Transplantation
Abstract

The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed... (More)

The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.

(Less)
Please use this url to cite or link to this publication:
@article{e6ba50f5-e550-472c-a242-ccd4e307043f,
  abstract     = {<p>The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.</p>},
  author       = {Sahebi, Firoozeh and Iacobelli, Simona and Sbianchi, Giulia and Koster, Linda and Blaise, Didier and Reményi, Péter and Russell, Nigel H. and Ljungman, Per and Kobbe, Guido and Apperley, Jane and Trneny, Marek and Krejci, Marta and Wiktor-Jedrzejczak, Wieslaw and Sanchez, James F. and Schaap, Nicolaas and Isaksson, Cecilia and Lenhoff, Stig and Browne, Paul and Scheid, Christof and Wilson, Keith M.O. and Yakoub-Agha, Ibrahim and Muñiz, Soledad González and Schönland, Stefan and Morris, Curly and Garderet, Laurent and Kröger, Nicolaus},
  issn         = {1083-8791},
  keyword      = {Immunomodulatory drugs,Multiple myeloma,Plerixafor,Proteasome inhibitors,Second primary malignancies},
  language     = {eng},
  publisher    = {Elsevier},
  series       = {Biology of Blood and Marrow Transplantation},
  title        = {Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents},
  url          = {http://dx.doi.org/10.1016/j.bbmt.2018.01.006},
  year         = {2018},
}